{"id":140018,"date":"2023-02-03T05:47:02","date_gmt":"2023-02-03T10:47:02","guid":{"rendered":"https:\/\/44.250.171.167\/?p=140018"},"modified":"2023-02-03T05:47:04","modified_gmt":"2023-02-03T10:47:04","slug":"divis-labs-ltd-nsedivislab-q3-fy23-results-outtotal-income-rises-5-yoy","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/divis-labs-ltd-nsedivislab-q3-fy23-results-outtotal-income-rises-5-yoy\/","title":{"rendered":"Divis Labs Ltd.(NSE:DIVISLAB )|Q3 FY23 Results Out|Total Income rises 5% yoy"},"content":{"rendered":"\n

Divi’s Laboratories Limited (NSE: DIVISLAB)<\/a> is a pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company operates globally, with facilities in India, the United States, and Europe, and serves customers in over 60 countries. Divi’s Laboratories is known for its strong focus on quality and innovation, and has a reputation for delivering high-quality products and services to its customers. The company’s API portfolio includes a wide range of products, including anti-cancer, anti-inflammatory, anti-viral, and cardiovascular drugs.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Divi’s Laboratories, a pharmaceutical company, announced its Q3FY23 results. The company reported a consolidated total income of Rs 1,822 crores for Q3FY23, a decrease from the total income of Rs 2,510 crores during the same quarter of last year. The Profit before Tax (PBT) for Q3FY23 was Rs 436 crores, a decrease from the PBT of Rs 1,034 crores in the corresponding quarter of the previous year. The Profit after Tax (PAT) for Q3FY23 was Rs 307 crores, also a decrease from the PAT of Rs 902 crores in the same quarter of the previous year. The company’s 9-month (9MFY23) performance showed a PAT of Rs 1,502 crores on a total income of Rs 6,099 crores, a decrease from the PAT of Rs 2,066 crores on a total income of Rs 6,503 crores in the previous period.<\/p>\n","protected":false},"excerpt":{"rendered":"

Divi’s Laboratories Limited (NSE: DIVISLAB) is a pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company operates globally, with facilities in India, the United States, and Europe, and serves customers in over 60 countries. Divi’s Laboratories is known for its strong focus on quality and innovation, and has a […]<\/p>\n","protected":false},"author":1932,"featured_media":140020,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392],"tags":[1408,1115],"class_list":["post-140018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","tag-pharma-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/fa084a5e-371a-4ccb-95c8-d5eeac5c1854-1.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170171,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":140018,"position":0},"title":"Divi’s Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 14, 2025","format":false,"excerpt":"Divi\u2019s Laboratories Limited, incorporated in 1990, is engaged in the manufacture and export of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b92,410 crore, up 13.79% year-on-year (YoY) from \u20b92,118 crore in Q1 FY25. Total Expenses: \u20b91,796\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DIVISLAB Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180421,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-reports-steady-q3-fy26-growth-amid-labour-code-impact\/","url_meta":{"origin":140018,"position":1},"title":"Divi’s Laboratories Reports Steady Q3 FY26 Growth Amid Labour Code Impact","author":"Staff Correspondent","date":"February 11, 2026","format":false,"excerpt":"Divi's Laboratories Limited (NSE: DIVISLAB), a leading Indian API manufacturer, posted consolidated total income of INR 2,692 crores for Q3 FY26 ended December 31, 2025, reflecting a 12% year-over-year increase from INR 2,401 crores. Q3 FY26 Consolidated Performance Profit before tax (PBT) reached INR 780 crores, up from INR 726\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":154677,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-pioneering-innovation-and-growth-in-the-pharmaceutical-frontier\/","url_meta":{"origin":140018,"position":2},"title":"Divi’s Laboratories: Pioneering Innovation and Growth in the Pharmaceutical Frontier","author":"Divyansh_Kasana","date":"September 20, 2023","format":false,"excerpt":"Stock Data: TickerNSE: DIVISLABSExchangeNSEIndustryPharmaceutical Price Performance: Last 5 Days+0.43 %YTD+12.23 %Last 12 Months+5.91 %As on 20-09-2023 Company Description: Divi's Laboratories is a leading pharmaceutical company headquartered in India, recognized for its excellence in research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and custom synthesis solutions. With a commitment to\u2026","rel":"","context":"In "Research Summary"","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/09\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/09\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/09\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/09\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/09\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/09\/f6ceac66-f2a3-45a2-ae80-d4455cad9356-2-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":129961,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":140018,"position":3},"title":"Divi’s Laboratories Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/MLu1npKFqZg Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY22 Earnings Concall Management Update: DIVISLAB said it reached milestone revenue for FY22 of $1 billion with decent profitability despite the hurdles faced during the pandemic. Q&A Highlights: Tushar Manudhane of Motilal Oswal asked if the company\u2019s steady-state growth of 13-15%\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":166862,"url":"https:\/\/alphastreet.com\/india\/divislab-q3-2024-2025-call-highlights-expansion-plans-generics-growth-and-api-challenges\/","url_meta":{"origin":140018,"position":4},"title":"DIVISLAB Q3 2024-2025 Call Highlights: Expansion Plans, Generics Growth, and API Challenges!","author":"Praveen","date":"February 13, 2025","format":false,"excerpt":"Divi's Laboratories Ltd., an Indian multinational pharmaceutical company that manufactures and exports API's, Intermediates and Nutraceutical ingredients, in its Q3 earnings call elaborated on several strategic initiatives and business segments. The management mentioned that the Kakinada facility's Phase I will be completed in 6 months, focusing on backward integration and\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/CC_Image_8.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":135727,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-q2fy23-19-fall-in-profits\/","url_meta":{"origin":140018,"position":5},"title":"Divi’s Laboratories Q2FY23; 19% Fall in Profits","author":"Karan_Singh","date":"November 7, 2022","format":false,"excerpt":"Divi's Laboratories Ltd.'s revenues in Q2FY23 fell 7% to \u20b9 1,855 crores. Consolidated Profit came at \u20b9 494 crores showcasing a 19% fall YoY over the corresponding period. In this quarter\u2019s\u00a0results, the reports suggested that the firm has observed a fall in profits due to a fall in revenue from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/Q2FY23-DIVISLAB-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/Q2FY23-DIVISLAB-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/Q2FY23-DIVISLAB-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/Q2FY23-DIVISLAB-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/Q2FY23-DIVISLAB-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=140018"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140018\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/140020"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=140018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=140018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=140018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}